Becton, Dickinson and Company · NYSE (us_market)
Healthcare · Medical Instruments & Supplies · United States
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. It operates through Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences segments. It provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow system, automated medication dispensing and supply management systems, informatics and analytics and pharmacy automation system, and medication inventory optimization and tracking system; hemodynamic monitoring system; and prefillable drug delivery systems. It also offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, and microorganism identification and drug susceptibility, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent system, and solution for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. It provides hernia and soft tissue repair, biological and bioresorbable graft, biosurgery, and other surgical products; surgical infection prevention, peripheral intervention, and urology and critical care products. The company has a strategic collaboration with ChemoGLO for the advancement of hazardous drug contamination testing in health care settings to improve the safety of health care workers. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.
| Event Period | Drawdown | Buy Point (Bottom) | Sell Point (Peak) | ticker.setupCols.buyScore | ticker.setupCols.sellScore | Max Return | Algo Return |
|---|---|---|---|---|---|---|---|
DROP2025-03-31$180.08 RISE2025-08-06$135.54 PEAK2025-08-22$156.97 144d | -24.7% 128d | Missed | Missed | — | — | +15.8% 16d | Missed |
DROP2025-03-18$182.48 RISE2025-06-20$132.41 PEAK2025-08-22$156.97 157d | -27.4% 94d | Missed | Missed | — | — | +18.5% 63d | Missed |
DROP2022-08-16$210.52 RISE2022-11-09$171.61 PEAK2023-01-06$203.88 143d | -18.5% 85d | Missed | Missed | — | — | +18.8% 58d | Missed |
DROP2022-08-16$210.52 RISE2022-10-10$172.81 PEAK2023-01-04$202.90 141d | -17.9% 55d | Missed | Missed | — | — | +17.4% 86d | Missed |
DROP2020-08-03$217.58 RISE2020-11-25$174.47 PEAK2021-01-20$201.95 170d | -19.8% 114d | Missed | Missed | — | — | +15.8% 56d | Missed |
DROP2020-04-27$207.09 RISE2020-06-25$175.59 PEAK2020-08-03$217.58 98d | -15.2% 59d | Missed | Missed | — | — | +23.9% 39d | Missed |
DROP2020-02-05$219.35 RISE2020-03-23$153.84 PEAK2020-04-27$207.09 82d | -29.9% 47d | Missed | Missed | — | — | +34.6% 35d | Missed |
Healthcare stocks declined late Friday afternoon, with the NYSE Healthcare Index decreasing 0.8% and
Hinde Group, an investment management company, has released its first-quarter 2026 investor letter. A copy of the letter is available to download here. The portfolio delivered a gross return of 3.80% and a net return of 3.41% in the first quarter, compared to a -4.33% return for the S&P 500 Index. The first quarter began with […]
ABT's Diagnostics unit witnesses mixed Q1 results as Core Lab growth offsets China weakness and softer respiratory testing demand.
Dividend growth among Kings accelerated to 3.71%, with notable increases from W.W. Grainger, Parker-Hannifin, and RLI Corp. Read more on Dividend Kings here.
BD (NYSE:BDX) has introduced the Elyra Thulium Fiber Laser System for kidney stone treatment, aiming to improve efficiency and flexibility in urologic procedures. The company also restated a long term global partnership with Bactiguard to broaden access to infection prevention catheter technology. Becton Dickinson sits at the intersection of medical devices, diagnostics, and interventional solutions, so updates in urology and infection prevention speak directly to its core business. The...
BD (NYSE:BDX) has introduced the Elyra Thulium Fiber Laser System for kidney stone treatment, aiming to improve efficiency and flexibility in urologic procedures. The company also restated a long term global partnership with Bactiguard to broaden access to infection prevention catheter technology. Becton Dickinson sits at the intersection of medical devices, diagnostics, and interventional solutions, so updates in urology and infection prevention speak directly to its core business. The...
BDX launches the Elyra Thulium Fiber Laser system to streamline kidney stone care and boost workflow flexibility for urology teams.
BDX launches the Elyra Thulium Fiber Laser system to streamline kidney stone care and boost workflow flexibility for urology teams.
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the introduction of the Elyra™ Thulium Fiber Laser (TFL) System, an advanced laser platform developed to complete BD's kidney stone care portfolio for urology teams. Designed to enhance efficiency, versatility, and procedural workflow across urologic stone management and soft tissue procedures, the innovative new system supports consistent performance in demanding clinical environments.
Stay updated with the movements of the S&P500 index one hour before the close of the markets on Tuesday. Discover which stocks are leading as top gainers and losers in today's session.
Stay informed about the performance of the S&P500 index in the middle of the day on Tuesday. Uncover the top gainers and losers in today's session for valuable insights.
Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today announced that Gerard (Jerry) Porreca has joined the company as Executive Vice President, Quality and Regulatory.
After the stock’s decline this year, do Wall Street analysts see a recovery in Becton, Dickinson and Company?
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Peter Menziuso has been named executive vice president and president, BD Interventional, effective June 1.
Becton, Dickinson and Company (NYSE:BDX) is included among the 11 Best Rising Dividend Stocks to Buy Right Now. On May 11, Barclays raised its price recommendation on Becton, Dickinson and Company (NYSE:BDX) to $204 from $202. It reiterated an Overweight rating on the shares following the company’s fiscal Q2 results. The firm said Becton delivered […]
Becton, Dickinson and Company (NYSE:BDX) is included among the 11 Best Rising Dividend Stocks to Buy Right Now. On May 11, Barclays raised its price recommendation on Becton, Dickinson and Company (NYSE:BDX) to $204 from $202. It reiterated an Overweight rating on the shares following the company’s fiscal Q2 results. The firm said Becton delivered […]
- 13F Filing
Becton, Dickinson and Company ( NYSE:BDX ) just reported healthy earnings but the stock price didn't move much...
Becton, Dickinson and Company ( NYSE:BDX ) just reported healthy earnings but the stock price didn't move much...
We recently published Jim Cramer Revealed His Big AI Investing Fear & Discussed These 20 Stocks. Becton, Dickinson and Company (NYSE:BDX) is one of the stocks discussed by Jim Cramer. Becton, Dickinson and Company (NYSE:BDX) is one of the largest medical devices and laboratory equipment providers in America. Its shares are up by 6.9% over […]
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| BDX | -1.47% | -16.66% | -3.57% | +8.43% |
| XLV | +2.97% | -5.72% | -3.44% | +12.69% |
| Alpha (stock − sector) | -4.44% | -10.95% | -0.13% | -4.26% |
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| StateStreet | passive | 13.82M | $2.17B | 0.08% | Trimmed-1.2% | 2026-03-31 |
| Wellington | fundamental | 6.62M | $1.04B | 0.19% | Added+24.8% | 2026-03-31 |
| FidelityFMR | fundamental | 1.09M | $170.86M | 0.01% | Trimmed-29.1% | 2026-03-31 |
| TwoSigma | quant | 36.6K | $5.75M | 0.00% | Unchanged | 2026-03-31 |
| Bridgewater | macro | 9.5K | $1.49M | 0.01% | Added+5.1% | 2026-03-31 |
| TRowePrice | fundamental | 4.42M | $694.84K | 0.08% | Added+3.3% | 2026-03-31 |
| Filed | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-05-27 | Feld Michael | EVP, Chief Revenue Officer | S Open-market sale | 75 | $147.35 | −$11.1K |
| 2026-05-08 | Roque Vitor | EVP & Chief Financial Officer | A Grant / award | 1,721 | — | +$0 |
| 2026-05-08 | Byington Carrie L | Director | A Grant / award(deriv) | 105 | $149.04 | +$15.6K |
| 2026-05-08 | Huffines Robert Luther | Director | A Grant / award(deriv) | 210 | $149.04 | +$31.3K |
| 2026-04-28 | Feld Michael | EVP, Chief Revenue Officer | S Open-market sale | 74 | $151.94 | −$11.2K |
| 2026-04-06 | Neal Shana Carol | EVP and Chief People Officer | F Tax withholding | 1,146 | — | +$0 |
| 2026-03-27 | Feld Michael | EVP, Chief Revenue Officer | S Open-market sale | 75 | $156.83 | −$11.8K |
| 2026-03-17 | Minnix Lanesha | EVP and General Counsel | A Grant / award | 7,492 | — | +$0 |
| 2026-03-04 | Spikner Pamela L. | SVP Controller & CAO | A Grant / award | 931 | — | +$0 |
| 2026-03-04 | Roque Vitor | Interim CFO | A Grant / award | 931 | — | +$0 |
| 2026-02-27 | Feld Michael | EVP, Chief Revenue Officer | S Open-market sale | 75 | $181.84 | −$13.6K |
| 2026-02-18 | SCOTT BERTRAM L | Director | S Open-market sale | 953 | $182.61 | −$174.0K |
| 2026-02-11 | BECTON DICKINSON & CO | 10% Owner | J Other acquisition | 284,771,350 | — | — |
| 2026-02-05 | Jones Christopher Ian Montague | Director | A Grant / award(deriv) | 272 | $201.91 | +$54.9K |
| 2026-02-05 | Byington Carrie L | Director | A Grant / award(deriv) | 30 | $201.91 | +$6.1K |
| 2026-02-05 | Huffines Robert Luther | Director | A Grant / award(deriv) | 100 | $201.91 | +$20.2K |
| 2026-01-29 | Wright Jacqueline | Director | A Grant / award | 1,098 | — | +$0 |
| 2026-01-29 | Waldstreicher Joanne | Director | A Grant / award | 1,098 | — | +$0 |
| 2026-01-29 | SCOTT BERTRAM L | Director | A Grant / award | 1,098 | — | +$0 |
| 2026-01-29 | RING TIMOTHY M | Director | A Grant / award | 1,098 | — | +$0 |
| 2026-01-29 | Jones Christopher Ian Montague | Director | A Grant / award | 1,098 | — | +$0 |
| 2026-01-29 | Huffines Robert Luther | Director | A Grant / award | 1,098 | — | +$0 |
| 2026-01-29 | Brown William M | Director | A Grant / award | 1,098 | — | +$0 |
| 2026-01-29 | HAYES GREGORY | Director | A Grant / award | 1,098 | — | +$0 |
| 2026-01-29 | Byington Carrie L | Director | A Grant / award | 1,098 | — | +$0 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-08-06upcoming | 3.12 | — | — |
| 2026-05-07 | 2.77 | 2.90 | +4.51% |
| 2026-02-09 | 2.80 | 2.91 | +3.88% |
| 2025-11-06 | 3.91 | 3.96 | +1.15% |
| 2025-08-07 | 3.40 | 3.68 | +8.16% |
| 2025-05-01 | 3.28 | 3.35 | +2.12% |
| 2025-02-05 | 2.99 | 3.43 | +14.74% |
| 2024-11-07 | 3.77 | 3.81 | +1.12% |
| 2024-08-01 | 3.31 | 3.50 | +5.80% |
| 2024-05-02 | 2.97 | 3.17 | +6.77% |
| 2024-02-01 | 2.40 | 2.68 | +11.64% |
| 2023-11-09 | 3.43 | 3.42 | -0.15% |
| 2023-08-03 | 2.91 | 2.96 | +1.58% |
| 2023-05-04 | 2.75 | 2.86 | +4.03% |
| 2023-02-02 | 2.68 | 2.98 | +11.03% |
| 2022-11-10 | 2.74 | 2.75 | +0.44% |